On Friday, September 5, the three major averages closed in the red following a weaker-than-expected US jobs report, which caused concerns about a slowing economy.

The Bureau of Labor Statistics reported that only 22,000 jobs were added in August, much less than the 75,000 jobs that economists polled by Dow Jones had expected. The unemployment rate also went up to 4.2%, which was in line with expectations.

The report increased the chances that the Federal Reserve will lower interest rates by at least a quarter-point at its meeting later this month.

On Friday, the S&P 500 dropped by 0.32%. The Nasdaq Composite lost 0.03%. The Dow Jones Industrial Average fell by 0.48%. Earlier in the session, all three indexes had reached new record intraday highs.

Even though stocks declined on Friday, the S&P 500 and the tech-heavy Nasdaq still finished the week with gains, gaining 0.33% and 1.14%, respectively. The Dow finished the week down 0.32%.

While the major indexes fell on Friday, the Russell 2000, which is the small-cap index, gained 0.48%. This performance on Friday helped the Russell 2000 achieve a fifth positive week in a row.

With this background in mind, let’s take a look at the top 10 stocks under $10 that could triple.

Our Methodology

To compile our list of the top 10 stocks under $10 that could triple, we used the Finviz stock screener to look for stocks with a share price of less than $10 and stocks that analysts believe can gain more than 200% over the next 12 months. We sorted our results based on market capitalization and picked the top 25 stocks that met these criteria as of September 5, 2025.

Next, we focused on the top 10 stocks most favored by institutional investors. Data for the hedge fund sentiment surrounding each stock was taken from Insider Monkey’s Q2 2025 database of 983 elite hedge funds. Finally, the top 10 stocks under $10 that could triple were ranked in ascending order based on the number of hedge funds holding stakes in them as of Q2 2025.

Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

Top 10 Stocks Under $10 That Could Triple

10. Sana Biotechnology, Inc. (NASDAQ:SANA)

Share Price: $2.96

Average Price Target Upside Potential According to Analysts: 204.57%

Number of Hedge Fund Holders: 16

Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the top stocks under $10 that could triple. On August 21, JMP Securities reaffirmed its Market Outperform rating for Sana Biotechnology, Inc. (NASDAQ:SANA) with a price target of $5.

This decision came after Sana Biotechnology, Inc. (NASDAQ:SANA) shared financial results and updates for the second quarter of 2025.

The research firm highlighted the six-month clinical results from the company’s ongoing UP421 study for type 1 diabetes (T1D) as the most important recent news.

JMP analysts pointed out that the modified pancreatic islet cell program is validating Sana Biotechnology, Inc.’s (NASDAQ:SANA) HIP platform for treating type 1 diabetes.

The firm also highlighted that the company’s iPSC program is advancing and the company plans to submit an IND filing in 2026. JMP analysts also pointed to another key catalyst for the company, the upcoming SC291 data for autoimmune disease (AID) expected in Q4 2025.

Sana Biotechnology, Inc. (NASDAQ:SANA) reported a pro forma Q2 2025 cash position of $177.2 million. JMP analysts noted that this is enough to support the company’s ongoing research and development efforts.

Sana Biotechnology, Inc. (NASDAQ:SANA) is a biotechnology company focused on developing and delivering engineered cells as a new class of medicines.

9. aTyr Pharma, Inc. (NASDAQ:ATYR)

Share Price: $5.61

Average Price Target Upside Potential According to Analysts: 230.06%

Number of Hedge Fund Holders: 16

aTyr Pharma, Inc. (NASDAQ:ATYR) is one of the top stocks under $10 that could triple. On August 22, Jefferies increased its price target for aTyr Pharma, Inc. (NASDAQ:ATYR) from $9 to $17 while keeping a Buy rating.

This decision comes ahead of the Phase 3 trial results for aTyr Pharma, Inc.’s (NASDAQ:ATYR) lead candidate, efzofitimod. The company plans to release topline data from its Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis in mid-September 2025.

Jefferies outlined three possible outcomes for the trial results. The firm sees a 37% chance of a strong positive result, showing a drop of more than 3mg in daily oral corticosteroid dose. According to the firm, this could cause aTyr Pharma, Inc.’s (NASDAQ:ATYR) stock price to rise by 3 to 5 times.

The firm sees a 23% chance for base case results, with a 1.87 to 3mg reduction, which could push the stock price 1 to 3 times higher. Jefferies assigned a 40% probability to negative results from the study, which could see the stock price fall by up to 75%.

Jefferies pointed out that there is a big unmet need for treatments for pulmonary sarcoidosis, which does not have any approved therapies yet. The firm noted that early Phase 1 and 2 proof-of-concept data showed encouraging signs, offering hope for positive outcomes in the Phase 3 trial.

aTyr Pharma, Inc. (NASDAQ:ATYR) is a clinical-stage biotechnology company focused on using evolutionary intelligence and tRNA synthetase biology to develop new treatments for diseases involving fibrosis and inflammation.

8. Wheels Up Experience Inc. (NYSE:UP)

Share Price: $2.00

Average Price Target Upside Potential According to Analysts: 1,395.33%

Number of Hedge Fund Holders: 19

Wheels Up Experience Inc. (NYSE:UP) is one of the top stocks under $10 that could triple. On August 20, Wheels Up Experience Inc. (NYSE:UP) reported that it has divested three non-core service businesses for about $20 million before transaction-related costs.

The three businesses that the company sold are Baines Simmons, Kenyon International Emergency Services, and Redline Assured Security. Wheels Up Experience Inc. (NYSE:UP) plans to reinvest the money from this sale to improve its fleet through modernization.

The sale of these three businesses is part of the company’s plan to strengthen its strategic focus. Wheels Up Experience Inc. (NYSE:UP) aims to invest in its products, fleet, and operations while also making its balance sheet stronger.

In addition to this sale, Wheels Up Experience Inc. (NYSE:UP) has also recently announced initiatives to drive about $50 million of cost efficiencies. These steps are expected to provide meaningful tailwinds, helping the company to grow profitably.

The sale of these non-core services businesses complements continued efforts to streamline Wheels Up’s business, drive operational performance and execute on the company’s fleet simplification and modernization strategy.

Wheels Up Experience Inc. (NYSE:UP) is one of the world’s largest private aviation companies. It provides on-demand private aviation services in the United States.

7. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Share Price: $2.49

Average Price Target Upside Potential According to Analysts: 200.60%

Number of Hedge Fund Holders: 25

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the top stocks under $10 that could triple. On August 19, H.C. Wainwright reaffirmed its Buy rating for Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) with a price target of $20.

This decision came after Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) reported that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for Amtagvi (lifileucel), a tumor-derived autologous T cell immunotherapy.

Amtagvi has been granted market authorization for the treatment of adult patients in Canada with unresectable or metastatic melanoma that has progressed after prior therapies. This authorization, which was based on safety and efficacy results from the C-144-01 trial, is conditional, awaiting results of trials to confirm the clinical benefits of Amtagvi.

In Canada, Iovance Biotherapeutics, Inc.’s (NASDAQ:IOVA) Amtagvi is the first T cell therapy approved for a solid tumor indication and the first treatment option approved for advanced melanoma after anti-PD-1 and targeted therapy.

H.C. Wainwright believes this authorization could prove to be an inflection point for Iovance Biotherapeutics, Inc.’s (NASDAQ:IOVA) stock, which has been under pressure recently. The Canadian authorization not only provides a new revenue stream but also paves the way for possible future approvals in other markets.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a commercial biotechnology company focused on developing tumor-infiltrating lymphocyte (TIL) therapies for patients with cancer.

6. Bicycle Therapeutics plc (NASDAQ:BCYC)

Share Price: $7.16

Average Price Target Upside Potential According to Analysts: 256.15%

Number of Hedge Fund Holders: 26

Bicycle Therapeutics plc (NASDAQ:BCYC) is one of the top stocks under $10 that could triple. On August 11, RBC Capital increased its price target on Bicycle Therapeutics plc (NASDAQ:BCYC) from $25 to $27 and kept an Outperform rating after the company reported its Q2 2025 results.

The research firm pointed out that the update on the Duravelo-2 dose selection is still expected in the fourth quarter of 2025. However, updates on Duravelo-1 are now expected in 2026, later than initially planned.

RBC Capital also highlighted Bicycle Therapeutics plc’s (NASDAQ:BCYC) efforts to reduce costs, mainly through a workforce reduction. This will help the company extend its cash runway into 2028. The company is focused on advancing its clinical programs through key milestones.

The firm is also confident that Bicycle Therapeutics plc’s (NASDAQ:BCYC) zelenectide could offer competitive efficacy compared to Padcev with an improved safety profile. RBC Capital indicated that the market is currently undervaluing the $2 billion oncology opportunity for zelenectide.

Previously, on August 8, Needham had also reiterated a Buy rating on Bicycle Therapeutics plc (NASDAQ:BCYC) with a $28 price target following the company’s Q2 2025 results.

Needham’s Buy rating reflects the company’s new plan to reduce costs by 30%. This move provides a stable foundation for Bicycle Therapeutics plc’s (NASDAQ:BCYC) ongoing projects and improves investor confidence about the company’s future.

Overall, analysts are bullish on Bicycle Therapeutics plc (NASDAQ:BCYC). The 12-month median price target of $25.50 set by analysts suggests a potential upside of 256% from the current stock price.

Bicycle Therapeutics plc (NASDAQ:BCYC) is a clinical-stage pharmaceutical company focused on developing a novel class of medicines, called Bicycle molecules, for diseases that are underserved by existing therapeutics, especially solid tumor cancers.

5. Relay Therapeutics, Inc. (NASDAQ:RLAY)

Share Price: $4.12

Average Price Target Upside Potential According to Analysts: 246.89%

Number of Hedge Fund Holders: 27

Relay Therapeutics, Inc. (NASDAQ:RLAY) is one of the top stocks under $10 that could triple. On September 4, Guggenheim began coverage of Relay Therapeutics, Inc. (NASDAQ:RLAY) with a Buy rating and a price target of $15.

Guggenheim analysts called Relay Therapeutics, Inc. (NASDAQ:RLAY) a “Best Idea” and questioned why it is trading below cash value despite having a strong pipeline.

The research firm focused on RLY-2608, Relay Therapeutics, Inc.’s (NASDAQ:RLAY) oral, selective, pan-mutant PI3Ka inhibitor. The RLY-2608 is currently in a fully-funded Phase 3 trial for breast cancer.

Guggenheim pointed out that RLY-2608’s Phase 1b progression-free survival was twice as long as expected compared to the control group. The firm believes that RLY-2608 has strong commercial potential, as many less effective drugs have quickly reached sales over $500 million. Relay Therapeutics, Inc. (NASDAQ:RLAY) is also ahead of its competitors in this mutant-selective class by 18 to 24 months.

In addition to oncology applications, Guggenheim sees potential for Relay Therapeutics, Inc.’s (NASDAQ:RLAY) RLY-2608 in treating vascular malformations (VM). The research firm believes that the company’s oncology-to-orphan thesis shift could lead to “substantial successes” similar to other biotech companies that shifted their strategies in a similar manner.

Relay Therapeutics, Inc. (NASDAQ:RLAY) is a clinical-stage, small molecule precision medicine company focused on developing therapies for cancer and genetic diseases.

4. Xencor, Inc. (NASDAQ:XNCR)

Share Price: $8.55

Average Price Target Upside Potential According to Analysts: 209.22%

Number of Hedge Fund Holders: 32

Xencor, Inc. (NASDAQ:XNCR) is one of the top stocks under $10 that could triple. On August 21, RBC Capital reduced its price target for Xencor, Inc. (NASDAQ:XNCR) from $32 to $15 and maintained an Outperform rating.

Despite lowering the price target, the firm believes that the current share price does not reflect the full value of Xencor, Inc.’s (NASDAQ:XNCR) business.

RBC Capital pointed to key areas of the company’s business that it sees as underappreciated. These include XmAb942, a monospecific anti-TL1A antibody, which has the potential for class-leading potency, for patients with inflammatory bowel diseases (IBD). Other areas of work that RBC sees as underappreciated include the immunology program focused on plamotamab and a bispecific platform in oncology where upcoming ENPP3 data could help reduce risks.

The firm also noted some challenges for Xencor, Inc. (NASDAQ:XNCR). These include limited data available for its programs, fewer near-term growth drivers outside oncology, and the need to advance development quickly.

Despite lowering the price target and acknowledging these concerns, RBC Capital suggested that it would still buy Xencor, Inc. (NASDAQ:XNCR).

Xencor, Inc. (NASDAQ:XNCR) is a clinical-stage biopharmaceutical company focused on developing engineered antibodies for cancer and autoimmune diseases.

3. Kura Oncology, Inc. (NASDAQ:KURA)

Share Price: $8.22

Average Price Target Upside Potential According to Analysts: 227.27%

Number of Hedge Fund Holders: 32

Kura Oncology, Inc. (NASDAQ:KURA) is one of the top stocks under $10 that could triple. On September 1, TipRanks reported that Charles Zhu from LifeSci Capital reiterated a Buy rating on Kura Oncology, Inc. (NASDAQ:KURA) with a $24 price target.

This decision reflects the potential of Kura Oncology, Inc.’s (NASDAQ:KURA) drug candidate KO-2806 in treating clear cell renal cell carcinoma (ccRCC). The upcoming presentations at ESMO 2025, especially the combination of KO-2806 with cabozantinib, could prove to be important opportunities to show that this treatment is both safe and effective.

Although farnesyl transferase inhibitors (FTIs) have faced many challenges in the past, KO-2806 could stand out. Its mechanistic similarities with mTORC1 inhibitors and its potential for improved tolerability make it a promising candidate.

Additionally, there is strong potential for Kura Oncology, Inc.’s (NASDAQ:KURA) KO-2806 to reach a 40% objective response rate (ORR) in combination with cabozantinib. This potential is more promising compared to current treatments.

The market seems to have overlooked this opportunity as Kura Oncology, Inc. (NASDAQ:KURA) is currently trading at a low enterprise value. There could be a strong upside if the clinical data can confirm the drug’s effectiveness.

Kura Oncology, Inc. (NASDAQ:KURA) is a clinical-stage biopharmaceutical company focused on developing targeted, well-tolerated treatments for cancer.

2. Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Share Price: $7.55

Average Price Target Upside Potential According to Analysts: 230.91%

Number of Hedge Fund Holders: 34

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) is one of the top stocks under $10 that could triple. On August 19, Piper Sandler started coverage of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) with an Overweight rating and set a price target of $25.

Piper Sandler noted that investor sentiment has weakened after the first two earnings reports of 2025 from Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) first two earnings reports of 2025. This has been caused mainly because of concerns about a possible plateauing of OJEMDA (tovorafenib) about a year after its launch.

The research firm described the recent stock decline as “overdone.” Piper Sandler believes that the early slowdown in OJEMDA’s performance can be attributed to the unique characteristics of its cancer indication. Prescribing physicians can be disinclined to take risks and adopt new therapies more slowly.

While growth may take longer than some investors expected, Piper Sandler is confident that OJEMDA’s strong clinical data will support solid long-term market penetration for Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN).

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) is a biopharmaceutical company focused on developing and commercializing first- or best-in-class medicines for pediatric and adult cancers.

1. 89bio, Inc. (NASDAQ:ETNB)

Share Price: $8.87

Average Price Target Upside Potential According to Analysts: 225.48%

Number of Hedge Fund Holders: 39

89bio, Inc. (NASDAQ:ETNB) is one of the top stocks under $10 that could triple. On September 4, H.C. Wainwright started coverage of 89bio, Inc. (NASDAQ:ETNB) with a Buy rating and a price target of $32.

The firm sees strong potential in 89bio, Inc.’s (NASDAQ:ETNB) lead candidate,pegozafermin, which is an FGF21 analog that imitates an endocrine hormone primarily expressed in the liver and has benefits for obesity and metabolic regulation.

89bio, Inc.’s (NASDAQ:ETNB) pegozafermin is now moving into several Phase 3 trials for different liver conditions. These include the ENTRUST trial for severe hypertriglyceridemia, where topline data is expected to be released in Q1 2026. The ENLIGHTEN Fibrosis trial for fibrosis stage F2-F3 is expected to deliver data in the first half of 2027. The ENLIGHTEN Cirrhosis trial for compensated cirrhosis (F4) is set to release data in 2028.

H.C. Wainwright pointed out that Phase 2B results were promising, showing significant improvement in fibrosis without worsening metabolic dysfunction-associated steatohepatitis (MASH) at Week 24. The data also showed reduced liver fat and improvements in biomarkers of liver injury and inflammation.

The firm further noted that pegozafermin showed safety and tolerability with lower rates of gastrointestinal side effects and no major clinical changes in bone biomarkers or bone mineral density.

89bio, Inc. (NASDAQ:ETNB) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and cardio-metabolic diseases.

While we acknowledge the potential of ETNB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ETNB and that has a 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Hot Mid Cap Stocks to Buy Now and 10 Best Affordable Stocks Under $50 to Buy.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.